XtalPi Inc., a leading AI-driven drug discovery firm based in Shenzhen and known as QuantumPharm Inc. (HKG: 2228), has announced a significant licensing agreement with Janssen Biotech, Inc., a subsidiary of Johnson & Johnson, for its proprietary AI platform, Ailux Biologics’ XtalFold. This platform, recognized for its innovative approach in biologics discovery, will be utilized by Janssen to enhance its biologics development and engineering capabilities.
XtalFold stands out as an AI-based software suite that offers rapid and precise structural insights, thereby accelerating biologics innovation across various stages. This technology represents a new frontier in drug discovery, as it uses sequence information to model biomolecular interactions, a critical aspect of biotherapeutics such as monoclonal antibodies. The platform has already demonstrated exceptional performance in benchmark studies, particularly in modeling challenging areas like the antibody-antigen interface.
The agreement comes on the wings of XtalFold’s successful validation in over 30 partner and internal programs, showcasing its impact in diverse applications, from antigen design to bispecifics design. This collaboration not only strengthens Janssen’s R&D efforts but also highlights the growing synergy between AI technology and pharmaceutical innovation.- Flcube.com
